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Background: Adherence to combination antiretroviral therapy (ART) is a key predictor of the success of human
immunodeficiency virus (HIV) treatment, and is potentially amenable to intervention. Insight into predictors or
correlates of non-adherence to ART may help guide targets for the development of adherence-enhancing
interventions. Our objective was to review evidence on predictors/correlates of adherence to ART, and to aggregate
findings into quantitative estimates of their impact on adherence.
Methods: We searched PubMed for original English-language papers, published between 1996 and June 2014, and
the reference lists of all relevant articles found. Studies reporting on predictors/correlates of adherence of adults
prescribed ART for chronic HIV infection were included without restriction to adherence assessment method, study
design or geographical location. Two researchers independently extracted the data from the same papers. Random
effects models with inverse variance weights were used to aggregate findings into pooled effects estimates with
95% confidence intervals. The standardized mean difference (SMD) was used as the common effect size. The
impact of study design features (adherence assessment method, study design, and the United Nations Human
Development Index (HDI) of the country in which the study was set) was investigated using categorical mixed
effects meta-regression.
Results: In total, 207 studies were included. The following predictors/correlates were most strongly associated
with adherence: adherence self-efficacy (SMD = 0.603, P = 0.001), current substance use (SMD = −0.395, P = 0.001),
concerns about ART (SMD = −0.388, P = 0.001), beliefs about the necessity/utility of ART (SMD = 0.357, P = 0.001),
trust/satisfaction with the HIV care provider (SMD= 0.377, P = 0.001), depressive symptoms (SMD = −0.305, P = 0.001),
stigma about HIV (SMD = −0.282, P = 0.001), and social support (SMD = 0.237, P = 0.001). Smaller but significant
associations were observed for the following being prescribed a protease inhibitor-containing regimen (SMD = −0.196,
P = 0.001), daily dosing frequency (SMD= −0.193, P = 0.001), financial constraints (SMD −0.187, P = 0.001) and pill
burden (SMD= −0.124, P = 0.001). Higher trust/satisfaction with the HIV care provider, a lower daily dosing frequency,
and fewer depressive symptoms were more strongly related with higher adherence in low and medium HDI countries
than in high HDI countries.
Conclusions: These findings suggest that adherence-enhancing interventions should particularly target psychological
factors such as self-efficacy and concerns/beliefs about the efficacy and safety of ART. Moreover, these findings suggest
that simplification of regimens might have smaller but significant effects.
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Adherence to combination antiretroviral therapy (ART)
is a key predictor of antiretroviral treatment success, and
is potentially amenable to intervention [1]. Sufficiently
high levels of adherence to ART are necessary to achieve
and sustain viral suppression and to prevent disease pro-
gression and death [2], yet, many patients infected with
human immunodeficiency virus (HIV)do not succeed in
achieving or maintaining adequate levels of adherence to
ART [3].
Insight into predictors or correlates of non-adherence
to ART offers the potential to identify patients at risk for
low levels of adherence. This would enable healthcare
providers to target those patients in most need, and to
tailor their care appropriately. Moreover, knowledge of
predictors/correlates of non-adherence to ART may help
guide targets for the development of interventions to
enhance or maintain adherence to ART.
Medication adherence is considered to be a complex be-
havior that is influenced by a wide range of factors, which
have previously been categorized into sociodemographic,
condition-related, treatment-related, patient-related, and
interpersonal factors [4,5]. In recent years, a number of
systematic reviews and meta-analyses have investigated
predictors/correlates of adherence by patients prescribed
ART for chronic HIV infection. One systematic review
provided a comprehensive assessment of predictors/corre-
lates of adherence to ART, but did not aggregate findings
into quantitative estimates of their effect on adherence
[5]. A number of other reviews did aggregate findings
into quantitative estimates, but focused only on patient-
reported barriers and facilitators [1], sociodemographic
factors [3], clinical, comorbid, and treatment-related
factors [6] and depression [7], or investigated a particular
patient population, such as drug users [8].
The objective of the present study was to carry out a
comprehensive review into the current research evidence
on sociodemographic, treatment-related, condition-related,
patient-related, and interpersonal predictors and correlates
of adherence to ART, and to aggregate the findings into
quantitative estimates of their impact on adherence.
Thereby, we aimed to assess the relative importance of
each predictor/correlate of adherence. Studies on adher-
ence to ART have been conducted in a variety of countries
and settings, and have used a variety of research designs
and adherence measurement methods. For these reasons,
another aim was to assess the impact of such study design
features on predictors/correlates of adherence.
Methods
Our meta-analysis was conducted in accordance with
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement guidelines [9]. Two
of the authors (NL and PN) searched PubMed for paperspublished from August 1996 to June 2014 using the
following strategy: Search: (((((“adult”[MeSH Terms]
AND hasabstract[text] AND ( “1996/01/01”[PDat] :
“2014/06/10”[PDat] ))) AND ((“patient compliance”[-
MeSH Terms] OR “medication adherence”[MeSH
Terms] AND hiv) AND hasabstract[text] AND ( “1996/
01/01”[PDat] : “2014/06/10”[PDat] ))) AND hasabstract
[text] AND ( “1996/01/01”[PDat] : “2014/06/10”[PDat] )))
NOT children[MeSH Terms] Filters: Abstract available,
From 1996/01/01 to 2014/06/10. Additionally, the refer-
ence lists of the papers retrieved were reviewed for add-
itional publications. Eligible studies had to meet the
following criteria: 1) original research study, 2) written
in English, 3) reporting on adult (older than 16 years of
age) patients infected with HIV who 4) were being pre-
scribed self-administered ART for chronic HIV infec-
tion, 5) using a quantitative method to assess adherence
to ART, and 6) reporting a statistical association between
a potential predictor/correlate and adherence. No geogra-
phical restrictions were applied. We excluded studies that
focused exclusively on the following specific populations:
drug users, prison inmates, homeless individuals, and
patients with psychiatric disorders.
We considered the following sociodemographic pre-
dictors/correlates of adherence: age, sex, and financial
constraints. Financial constraints were defined as being
unemployed or having an income level in the lowest
category as defined within a particular study. Treatment-
related predictors/correlates were: duration of ART, num-
ber of prescribed antiretroviral pills per day (that is, pill
burden), daily dosing frequency, and whether or not
the regimen contained a protease inhibitor (PI). Disease-
related predictors/correlates included CD4 cell count and
time since HIV diagnosis. We also investigated interper-
sonal predictors/correlates: social support, HIV stigma
and trust or satisfaction with the HIV care provider. Fi-
nally, patient-related predictors/correlates were current
substance use (alcohol and drugs), depressive symptoms,
adherence self-efficacy (the extent to which patients believe
that they will be able to adhere), motivation to adhere,
locus of control (the extent to which individuals believe
that they can control events that affect them), concerns
about adverse effects of ART, and beliefs in the necessity
or utility of ART.
Two authors (NL and PN) independently extracted
data from each study that fulfilled the inclusion criteria,
using a scoring sheet. The following information was
extracted: name of the first author, year of publication,
sample size, country in which the study was conducted,
year study was started, adherence assessment method
(self-report, electronic monitoring devices (EMD), phar-
macy refill, pill count), and whether patients were initiat-
ing, restarting, or switching an ART regimen, or were
already on ART, and the potential predictors or correlates
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as the adherence measurement were considered to be
correlates, and factors assessed prior to the adherence
measurement were considered to be predictors. Because
we included studies conducted in any country around the
world, we categorized countries according to the United
Nations Human Development Index (HDI) [10] during
the year the study was started into low (HDI ≤ 0.50),
medium (HDI of 0.50 to 0.79), and high (HDI ≥ 0.80)
development countries.
When data from the same study were reported in
multiple publications, we selected the publication that
had the largest sample size and/or reported the largest
number of predictors/correlates. If the study evaluated
adherence at multiple time points, the value of the first
measurement was used to avoid dependence. When rela-
tionships between predictors/correlates and adherence were
reported for discrete subgroups within a single study, the
groups were included as independent samples.
The quality of the reporting of the included studies
was assessed using the 22 items recommended by the
Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement [11]. Items fulfilling
the STROBE statement were considered positive and
items not fulfilling the statement were as–considered
negative.
Statistical analysis
We used the standardized mean difference (SMD) as the
common effect size to express the magnitude of the
association between predictors/correlates and adherence.
If studies did not provide the SMD, we calculated it from
r, correlation coefficient means and standard deviations,
odds ratios, t-test, χ2 test, or F-statistic, contingency table
data, or exact P values [12]. When studies reported an
insignificant association without data, we assigned it an
SMD of 0.001. We adjusted the SMD using the small sam-
ple size bias correction prior to analysis. SMD values of
0.2, 0.5, and 0.8 were interpreted as small, medium. and
large effects, respectively [13].
Predictors/correlates were selected for quantitative
pooling if 10 or more independent effect sizes could be
calculated. Random effect models with inverse variance
weights were used to aggregate individual effect sizes
into pooled effect estimates with 95% confidence limits
(CI), using the SPSS macro MeanES from Lipsey and
Wilson [12,14].
We examined whether the effect sizes differed sig-
nificantly across levels of potential moderators of the
predictor-adherence relationship, if there was hetero-
geneity across studies (I2 > 50%) and sufficient data (k > 4
in each subgroup) to support these analyses [15]. The
following study design features were investigated as
potential moderators: whether the factor was a predictoror correlate, whether the adherence assessment method
was self-report (versus all other methods) or EMD (versus
all others), whether the study was conducted in a high
HDI country (versus medium and low HDI country), and
whether patients were already on ART (versus initiating,
restarting, or switching ART). For the moderator analyses,
subgroup analyses were performed by grouping effect
sizes by study design feature and assessing heterogen-
eity between groups using the between-group Q statistic
(Q-between) within a mixed effects model using the me-
thod of moments estimation. If Q-between is significantly
greater than the heterogeneity within groups due to error
(Q-within), this indicates that a moderator variable ex-
plains a significant proportion of the total heterogeneity in
effect sizes. The moderator analyses were conducted using
the SPSS macro MetaF from Lipsey and Wilson [12,14].
Results
Figure 1 shows the study selection process. In total, 207
studies were included in our analysis, reporting on
103,836 patients [16-222]. Two hundred studies consisted
of one independent sample for calculating effect sizes, five
studies consisted of two samples and two studies consisted
of three samples, resulting in a total of 216 independent
samples (k = 216). A total of 67% (k = 145) of the samples
reported on correlates of adherence, and 33% (k = 71) on
predictors. A total of 54% (k = 117) of the samples inclu-
ded patients already on ART and 46% (k = 99) included
patients who were (re)starting or switching. The following
adherence assessment methods were used: 77% self-
report (k = 166), 11% EMD (k = 23), 8% (k = 18) a phar-
macy refill-based measure and 4% (k = 9) a pill count-based
measure. A total of 67% (k = 145) of the samples originated
from countries with a high HDI, 19% (k = 40) from coun-
tries with a medium HDI, and 14% (k = 31) from countries
with a low HDI. For characteristics of the included studies,
see Additional file 1.
Locus of control and motivation to adhere were excluded
from our analysis because fewer than 10 independent ef-
fect sizes could be calculated for these two predictors/
correlates.
The strongest association with adherence was found for
the predictor/correlate adherence self-efficacy, with the
pooled effect size being medium to large (SMD= 0.603,
95% CI 0.47 to 0.73, k = 39, P = 0.001; Figure 2 (1.1.1)).
The following predictors/correlates were significantly
associated with adherence, with their effect sizes being
small to medium: current substance use (SMD= −0.395,
95% CI −0.49 to −0.30, k = 80, P = 0.001), concerns
about ART (SMD= −0.389, 95% CI −0.53 to −0.25, k = 14,
P = 0.001), trust/satisfaction with the HIV healthcare pro-
vider (SMD= 0.377, 95% CI 0.29 to 0.46, k = 30, P = 0.001),
beliefs about the necessity/utility of ART (SMD= 0.357,
95% CI 0.23 to 0.49, k = 25, p = 0.001), depressive symptoms
Figure 1 Flow diagram of the study selection process.
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HIV stigma (SMD= −0.282, 95% CI −0.36 to −0.21, k = 47,
P = 0.001) and social support (SMD= 0.237, 95% CI 0.18
to 0.29, k = 67, P = 0.001). The predictors/correlates yielding
small to medium effects are shown in Figure 2 (1.1.2).
The following predictors/correlates were signifi-
cantly associated with adherence with their effect sizes
being small: being prescribed a PI-containing regimen
(SMD= −0.196, 95% CI −0.27 to −0.12, k = 26, P = 0.001),
daily dosing frequency (SMD = −0.193, 95% CI −0.25
to −0.14, k = 29, P = 0.001) and financial constraints
(SMD= −0.187, 95% CI −0.24 to −0.14, k = 110, P = 0.001).The predictors/correlates with small effect sizes are shown
in Figure 2 (1.1.3).
The following predictors/correlates were significantly
associated with adherence but their effect sizes were very
small: pill burden (SMD= −0.124, 95% CI −0.18 to −0.07,
k = 57, P = 0.001), age (SMD = 0.118, 95% CI 0.089 to
0.147, k = 158, P = 0.001), time since HIV diagnosis
(SMD = −0.116, 95% CI −0.17 to −0.06, k = 57, P = 0.001)
and male gender (SMD = 0.081, 95% CI 0.037 to 0.12,
k = 142, P = 0.001). The predictors/correlates with very
small effect sizes are shown in Figure 2 (1.1.4). Two
predictors/correlates were not significantly associated with
Figure 2 Predictors/correlates of adherence to anti-retroviral therapy (ART).
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to 0.048, k = 67, P = 0.64) and duration of ART (SMD=
0.003, 95% CI −0.047 to 0.052, k = 51, P = 0.92).
For forest plots of the individual studies examining
predictors/correlates, see Additional file 2. For the scoring
of included studies according to the items of the STROBE
statement, see Additional file 3.
The study design feature “HDI of the country in which
the study was conducted” was significantly associated
with four predictors/correlates. Trust/satisfaction with the
HIV care provider was more strongly associated with
adherence in countries with a low or medium HDI than in
countries with a high HDI (Figure 3 (1.2.3); Q-between =
8.04, P = 0.005). Daily dosing frequency was more strongly
and negatively associated with adherence in countries with
a medium or low HDI than in countries with a high HDI
(Figure 3 (1.2.2); Q-between = 3.88, P = 0.049). Older age
was associated with higher adherence in countries with a
high HDI but not in countries with a medium or low HDI
(Figure 3 (1.2.1); Q-between = 5.16, P = 0.02). Depressive
symptoms were more strongly associated with lower
levels of adherence in countries with a medium or
low HDI than in countries with a high HDI (Figure 3
(1.2.4); Q-between = 4,38, P = 0.04).
The adherence assessment method was significantly
associated with two predictors/correlates. Adherence self-
efficacy was more strongly associated with adherence instudies using self-report as adherence assessment method
than in studies using another method (Figure 4 (1.3.2);
Q-between = 6.94, P = 0.008). Older age was more strongly
associated with adherence in studies using EMD as adher-
ence assessment method than in studies using another
method (Figure 4 (1.3.1); Q-between = 10.12, P = 0.002).
Whether investigated factors were predictors or corre-
lates yielded two significant associations. Trust/satisfac-
tion with the HIV care provider was more strongly related
with adherence if assessed as a correlate than if assessed
as a predictor (Figure 4 (1.3.4); Q-between =7.44, P = 006).
Current substance use was more strongly and negatively
related with adherence if assessed as a correlate than as a
predictor (Figure 4 (1.3.3); Q-between = 6.34, P = 0.012).
Discussion
In our meta-analysis based on 207 papers reporting on
103,836 patients, we obtained a comprehensive overview
of the relative importance of various predictors/corre-
lates of adherence to ART. Adherence to ART was most
strongly associated with patients’ beliefs, that is, adherence
self-efficacy beliefs, concerns about adverse effects of
ART, and beliefs about the necessity/utility of ART, and
also with current substance use, trust or satisfaction with
the HIV care provider, depressive symptoms, HIV stigma,
and social support. Aspects of regimen complexity, such
as daily dosing frequency, pill burden, and whether the
Figure 3 Countries Human Development Index (HDI) as moderator of the predictor-adherence relationship.
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effects.
Our findings are consistent with a recent meta-analysis
of patients with various long-term medical conditions,
showing that patients’ beliefs have an important influence
on medication adherence [223]. Results are also consistent
with previous studies showing that substance use, depres-
sive symptoms, and HIV stigma are associated with lower
levels of adherence, and trust or satisfaction with the
healthcare provider are associated with higher levels of
adherence [7,8,180,224]. These results should be en-
couraging to HIV care providers, as they suggest severalFigure 4 Adherence assessment method and design as moderators oavenues for intervention that could result in improved
adherence. In particular, patients’ adherence-related beliefs
and the relationship between the patient and their HIV
care provider are factors that are in principle modifiable,
and thus possible targets for adherence-enhancing inter-
ventions. Eliciting and addressing patients’ beliefs and
promoting an improved relationship between patient and
healthcare provider have previously been associated with
improved levels of adherence [225,226].
This study has several limitations. We aimed to provide
a global overview of the relative importance of various
predictors/correlates of adherence to ART. Therefore,f the predictor-adherence relationship.
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categories, for example, social support, HIV stigma, trust
or satisfaction with the HIV healthcare provider, financial
constraints, and substance use. Within these broad
categories, distinct types of predictors/correlates may
have a different impact on adherence, which would
have remained undetected in the present global analysis;
for example, alcohol use could have a different impact on
adherence compared with cocaine use.
Another limitation is that the search was performed
using a single database (PubMed) only, and included only
published English-language papers. This may have influ-
enced our results.
However, this meta-analysis has also several strengths.
It provides a comprehensive overview of predictors/cor-
relates of adherence to ART, with quantitative estimates
of their impact. Moreover, this meta-analysis provides
information about the relative importance of predictors/
correlates.
Papers were included without restriction to geographical
region, adherence assessment method, or study design.
This probably resulted in a consequently large heterogen-
eity in effect sizes for most predictors/correlates. Guide-
lines for the reporting of meta-analyses of observational
studies have recommended using broad inclusion criteria
and then performing analyses relating design features to
outcomes [227]. We thus conducted meta-regression ana-
lyses to explore the impact of study design features on
predictors/correlates of adherence.
The study design feature “HDI of the country in which
the study was conducted” was significantly associated
with four predictors/correlates. Trust/satisfaction with
the HIV healthcare provider had a stronger positive effect
on adherence in countries with a low or medium HDI
than in countries with a high HDI. A possible explanation
for this is that in countries with low or medium HDI,
patients are more dependent on their HIV healthcare
provider for information, support, and care. Conversely, in
countries with a high HDI, patients usually have more
extensive access to healthcare providers and to informa-
tion about health, HIV, and ART, making them less
dependent on their HIV healthcare provider. There could
also be cultural differences in the relationship between
patients and healthcare providers, with the healthcare pro-
viders having more authority in low or medium income
countries.
Daily dosing frequency was more strongly and nega-
tively associated with adherence in countries with a
medium or low HDI than in countries with a high HDI.
One possible explanation is that achieving or maintain-
ing high levels of adherence is more challenging in low
or medium HDI countries. The added challenge of more
frequent daily dosing could therefore more easily result
in lower levels of adherence in these countries. However,this explanation is in contrast to results from previous
studies showing higher levels of adherence in low income
countries than in high income countries [3,228].
Older age was associated with higher adherence in
countries with a high HDI but not in countries with a
medium or low HDI. This finding could simply reflect
the fact that studies from low and medium HDI countries
included few older patients. Finally, depressive symptoms
were more strongly and negatively associated with adher-
ence in countries with a medium or low HDI than in
countries with a high HDI.
A remarkable finding was the limited effect of the
adherence assessment method on effect sizes. Self-reports
are known to overestimate adherence. We expected to
find stronger associations between predictors/correlates
and adherence in studies using EMDs than in studies
using self-reports because EMDs are usually considered to
be a more valid adherence assessment method [229]. A
possible explanation for the limited effect of the adherence
assessment method could be that although self-reports
overestimate adherence, the rank order of patients on an
adherence scale is similar for self-report and electronic
monitoring, thus yielding similar associations.
Duration of ART was not related to adherence in the
present meta-analysis. It is usually assumed that adher-
ence declines with increasing length time on treatment.
However, a recent study investigating the natural history
of changes in adherence to ART over time has shown
that the decline is non-linear, with substantial hetero-
geneity across studies [230]. In view of these results and
the fact that the present meta-analysis included both
patients already on ART and patients (re)starting ART,
the absence of a relation between duration of ART and
adherence is not surprising.
Conclusions
This meta-analysis of predictor/correlates of ART showed
that adherence was strongly related to patients’ adherence-
related beliefs. These findings suggest that adherence-
enhancing interventions should target psychological factors
such as self-efficacy and necessity/concerns beliefs about
ART. Additionally, simplification of regimens may have
smaller, albeit significant effects.
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